Berlin (ots) - Die Präsidiumsmitglieder des Deutschen Raiffeisenverbandes (DRV) haben heute den ...
ots Ad hoc-Service: Qiagen N.V.
AGILENT AND QIAGEN GENOMICS ENTER INTO SNP GENOTYPING AGREEMENT
Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Venlo,NL (ots Ad hoc-Service) - Karen Hedine General Manager QIAGEN Genomics, Inc. (425)398-3140 email: firstname.lastname@example.org Peer M. Schatz Chief Financial Officer QIAGEN N.V. 011-49-2103-2911-702 email: p.schatz@de.QIAGEN.com Noonan/Russo Communications, Inc. Mary Claire Bice (212)696-4455 AGILENT AND QIAGEN GENOMICS ENTER INTO SNP GENOTYPING AGREEMENT This significant Alliance links Agilent's leading position in mass spectrometry with QIAGEN Genomics' technologies and MasscodeTM consumables. Agilent Technologies, Inc. (NYSE: A), a leading vendor of communications and life sciences solutions and QIAGEN Genomics, Inc., a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Frankfurt Neuer Markt: QIA; EASDAQ: QGEN), today announced that they have entered into an exclusive value-added reseller agreement. The agreement intends to leverage Agilent's single-quadrupole LC/MS with QIAGEN Genomics' Masscode technologies and consumables to provide single nucleotide polymorphism (SNP) genotyping systems to be marketed by QIAGEN Genomics. In the second phase of the agreement, both companies will jointly develop new Masscode tag chemistry and mass spectrometry instrumentation solutions for SNP discovery, proteomics and other applications. Agilent, a market and technology leader in single quadrupole mass spectrometry further agreed to exclusively optimize its mass spectrometry systems for use with QIAGEN Genomics' MasscodeTM technologies for SNP-genotyping. Under the terms of the agreement, QIAGEN Genomics will exclusively promote its MasscodeTM technologies on Agilent's systems. The parties are committed to devise and develop applications of their technologies that will be used by pharmaceutical companies to develop better drugs and to advance disease discovery and pharmacogenetic research. Financial details of the deal were not disclosed. QIAGEN Genomics is a market and technology leader in genotyping technologies. The company and its clients use single quadrupole mass spectrometer instrumentation, MasscodeTM tags as well as other QIAGEN technologies for cost effective high throughput SNP genotyping with highest data quality standards. Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's, QIAGEN Genomics' and Agilent's technologies, services, products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with the challenges in integrating newly-acquired businesses into QIAGEN's operations, management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the adoption and integration of new technologies, products and services, the commercial development of the DNA sequencing and genomics market, proteomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for genomics services (including seasonal fluctuations), difficulties in successfully developing the companies' technologies, services and products and combining these into integrated solutions and providing such products and services, the companies' ability to identify and develop new products and services and to differentiate their products and services from competitors. For further information pertinent to QIAGEN and QIAGEN Genomics refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC). End of Message ----------------------------------------------------- Internet: http://recherche.newsaktuell.de Original-Content von: Qiagen N.V., übermittelt durch news aktuell